Clinical Trial Update: Effect of Pretreatment With Ticagrelor on Residual Thrombus After PCI in Patients Presenting With ACS in Comparison With Delayed Treatment at the Time of PCI: an OCT Study [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating pretreatment with ticagrelor to reduce residual thrombus after PCI in patients with acute coronary syndrome has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Coronary Syndrome

Drugs mentioned

• TICAGRELOR (ticagrelor)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Acute Coronary Syndrome, Coronary Artery Disease | Phase 4 | Status: WITHDRAWN